6,265 Shares in GSK plc (NYSE:GSK) Bought by Cetera Trust Company N.A

Cetera Trust Company N.A bought a new stake in GSK plc (NYSE:GSK) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 6,265 shares of the pharmaceutical company’s stock, valued at approximately $232,000.

A number of other institutional investors have also recently bought and sold shares of GSK. Versant Capital Management Inc lifted its position in GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 676 shares during the last quarter. Fairfield Bush & CO. acquired a new position in GSK in the 2nd quarter valued at $28,000. BKM Wealth Management LLC acquired a new stake in shares of GSK during the fourth quarter worth $32,000. Larson Financial Group LLC boosted its position in shares of GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 647 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in GSK by 61.3% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on GSK shares. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Morgan Stanley began coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.

GSK Trading Up 0.9 %

NYSE:GSK opened at $40.11 on Monday. The firm has a market cap of $83.13 billion, a P/E ratio of 13.21, a P/E/G ratio of 1.40 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. GSK plc has a 52 week low of $33.33 and a 52 week high of $43.84. The firm’s fifty day moving average is $41.89 and its 200-day moving average is $38.83.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. Equities analysts expect that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were paid a $0.3564 dividend. The ex-dividend date was Thursday, February 22nd. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.55%. GSK’s dividend payout ratio (DPR) is currently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.